Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Share News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Midatech Pharma up 90% on Q-Sphera breakthrough

Thu, 17th Jun 2021 11:43

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

----------

AIM - WINNERS

----------

Midatech Pharma PLC, up 89% at 51.90 pence, 12-month range 18.10p-87.00p. The biotechnology company says it has data demonstrating that its Q-Sphera technology can formulate monoclonal antibodies into long-acting injectables, a novel development in pharmaceuticals with significant medical and commercial potential. "The company believes no other commercial or academic organisation has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling," it says.

----------

Blue Prism Group PLC, up 7.4% at 964.50p, 12-month range 883.50p-1,900.00p. The robotic process automation firm posts narrowed interim loss after seeing growing revenue and booking numbers for the period. Blue Prism reports a pretax loss of GBP21.0 million for the six months ended April 30, sharply narrowed from GBP53.8 million a year prior. Bookings grew 35% in the first half to GBP98 million, or 39% at constant currency. Revenue for the period increased by 21% year-on-year to GBP80.4 million from GBP66.6 million, with recurring, subscription-based, licence revenue accounting for a 98% share.

----------

AIM - LOSERS

----------

Open Orphan PLC, down 14% at 30.00p, 12-month range 11.16p-34.50p. The pharmaceutical services company posts 2020 pretax loss GBP11.2 million, widened from GBP5.8 million on revenue from continuing operations of GBP20.6 million, up from GBP3.4 million. Separately, Poolbeg Pharma confirms plan to float on AIM as a spinoff of Open Orphan. Poolbeg Pharma to use IPO raise to fund clinical trial of treatment for severe influenza.

----------

Cake Box Holdings PLC, down 7.3% at 266.50p, 12-month range 155.00p-356.00p. The eggless deserts maker notes movement in shares. It confirms that it has recently emailed customers in relation to a data breach experienced in 2020 as a result of which personal and financial information may potentially have been accessed. Cake Box says it has taken the appropriate steps to investigate the incident, repair the compromised systems, and identify those customers that may have been compromised. It also has further strengthened the security of its systems to prevent future breaches, it says. "The company confirms that the data breach is not expected to have a material financial impact and as per the announcement on 12 April 2021, full year results are expected to be in line with market expectations," Cake Box adds.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
9 Jul 2021 11:42

Open Orphan inks contract with AIM ImmunoTech to test Ampligen drug

Open Orphan inks contract with AIM ImmunoTech to test Ampligen drug

Read more
9 Jul 2021 10:52

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle

Read more
9 Jul 2021 10:20

Open Orphan subsidiary scores 'significant contract' with AIM ImmunoTech

(Sharecast News) - Clinical research organisation Open Orphan's hVIVO subsidiary has signed "a significant contract" to test AIM ImmunoTech's antiviral candidate, Ampligen.

Read more
17 Jun 2021 14:34

Cathal Friel-led Poolbeg Pharma set to float on AIM

(Sharecast News) - Infectious disease specialist Poolbeg Pharma is to list on the London Stock Exchange's junior market, AIM, with a view to raising the funds needed to develop its product pipeline.

Read more
17 Jun 2021 14:05

Open Orphan reports widened 2020 loss; Poolbeg mulls London float

Open Orphan reports widened 2020 loss; Poolbeg mulls London float

Read more
16 Jun 2021 16:00

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
19 May 2021 19:33

TRADING UPDATES: Young's mulls asset sale; Ceres gets China investment

TRADING UPDATES: Young's mulls asset sale; Ceres gets China investment

Read more
10 May 2021 13:37

TRADING UPDATES: Begbies buys finance broker; Amino Tech makes US bid

TRADING UPDATES: Begbies buys finance broker; Amino Tech makes US bid

Read more
10 May 2021 09:30

Open Orphan subsidiary signs contract to make Covid-19 challenge virus

(Sharecast News) - Specialist pharmaceutical services contract research organisation Open Orphan announced on Monday that its subsidiary hVIVO has signed a contract with Imperial College London, as part of a Wellcome Trust-funded initiative to manufacture a SARS-CoV-2 challenge virus.

Read more
6 May 2021 15:33

EXECUTIVE CHANGES: New Cenkos CEO gets FCA nod; Feedback hires CFO

EXECUTIVE CHANGES: New Cenkos CEO gets FCA nod; Feedback hires CFO

Read more
9 Apr 2021 10:33

Open Orphan launches new data platform to combat infectious diseases

Open Orphan launches new data platform to combat infectious diseases

Read more
26 Mar 2021 14:36

TRADING UPDATES: Renew to buy J Browne; Idox in good start to year

TRADING UPDATES: Renew to buy J Browne; Idox in good start to year

Read more
25 Mar 2021 17:14

TRADING UPDATES: SpaceandPeople swings to loss in 2020 amid virus

TRADING UPDATES: SpaceandPeople swings to loss in 2020 amid virus

Read more
25 Mar 2021 15:34

Open Orphan makes progress with Covid-19 characterisation study

(Sharecast News) - Specialist pharmaceutical services clinical research company Open Orphan updated the market on its world-first Covid-19 characterisation study on Thursday, reporting that the first three volunteers had now completed the quarantine phase.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.